Bone health in teens and young adults taking GLP-1 weight loss drugs
Part of Hormones & metabolism clinical trials.
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 21 years old.
- You have obesity (BMI at or above the 95th percentile for your age and sex).
- You are either starting a GLP-1 RA medication (except dulaglutide or exenatide) or are receiving usual weight management care.
- You have not had weight loss surgery or lost more than 11 pounds in the last 3 months.
- You do not have a personal or family history of medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2 (if you are taking the GLP-1 drug).
- You must be willing to use specific birth control methods (if female and sexually active) and cannot have used Depo-Provera shots.
- You do not have untreated thyroid problems or conditions that affect bone, like inflammatory bowel disease or rheumatoid arthritis.
- You are not pregnant or breastfeeding, and have no history of pregnancy.
- You do not smoke more than 10 cigarettes a day or have substance abuse issues.
- Your weight is under 450 pounds (for bone scan limits) and your blood sugar control (HbA1c) is 8% or lower.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how GLP-1 receptor agonist drugs (used for weight loss) affect muscle mass and strength in people with obesity who do not have diabetes. It may help understand if these medications impact muscle health.
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
This study tests whether a 12-week program of exercise and personalized nutrition can help adults who are obese and taking GLP-1 weight-loss medications maintain muscle and bone while losing fat. It aims to improve strength, fitness, and overall function during treatment.
This study is for people who have lost weight using GLP-1 injections (like semaglutide or tirzepatide) and are thinking about stopping them. It tests whether switching to an oral weight-loss medication can help you keep the weight off.
This study looks at how teenagers and young adults respond to weight-loss surgery (sleeve gastrectomy) and whether adding a medication called semaglutide can help improve weight loss. It has two parts: first observing how surgery affects you, then testing if semaglutide helps those who didn't lose enough weight after surgery.
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
Hear when a new Obesity in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.